Early testing of convalescent plasma: ‘building the plane while flying it’
Getting an expanded access protocol for convalescent plasma off the ground and testing it as a Covid-19 therapy was a wild ride.
Related Articles
Program Guide – ASCO Meeting Program Guide
Suresh Ramalingam Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute Suresh Ramalingam, Terufumi Kato, Xiaorong Dong, Myung-Ju Ahn, Le-Van…
Program Guide – ASCO Meeting Program Guide
Joseph Greer Massachusetts General Hospital, Harvard Medical School Joseph Greer, Chardria Trotter, Vicki Jackson, Simone Rinaldi, Mihir Kamdar, Areej El-Jawahri, Nora Horick, Kedie Pintro, Dustin…
#PallOnc – Healthcare Social Media Analytics and Transcripts
In an effort to ensure that oncology professionals are providing the highest-quality care, ASCO strives to offer resources and forums to discuss the best
Program Guide – ASCO Meeting Program Guide
Christian Blank Netherlands Cancer Institute (NKI-AVL), Department of Medical Oncology Christian Blank, Minke Lucas, Richard Scolyer, Bart van de Wiel, Alexander Menzies, Marta Lopez-Yurda, Alexander…
Program Guide – ASCO Meeting Program Guide
Jens Hoeppner, Thomas Brunner, Florian Lordick, Claudia Schmoor, Birte Kulemann, Ulf Peter Neumann, Gunnar Folprech t, Tobias Keck, Frank Benedix, Maximilan Schmeding, Ernst Reitsamer, Christiane…
RAS/RAFlandscape in monoclonal plasma cell conditions.
Key Points. RAS/RAF mutations are present in up to 61% of patients with multiple myelomaMost of them are subclonal, in agreement with a secondary event
Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
PURPOSE Promising single-agent activity from sotorasib and adagrasib in KRASG12C-mutant tumors has provided clinical evidence of effective KRAS signaling inhibition. However, comprehensive analysis of KRAS-variant…
Real-World Clinical Genomic Analysis of Patients with BRAF Mutated Cancers Identifies BRAF Class II and III as a Population of Unmet Medical Need – Tempus
Background Oncogenic BRAF mutations can be categorized into three classes (I, II and III) based on their distinct structural and signaling properties. BRAF inhibitors are…
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO’s membership following publication or presentation of potentially practice-changing data from major studies. This…
Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA
npj Precision Oncology – Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA